Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.3 NOK | -2.62% | -2.19% | -4.29% |
Mar. 04 | Vistin Pharma ASA (OB:VISTN) acquired 15% stake in CF Pharma Ltd. for ?1.6 million. | CI |
Feb. 16 | Vistin Pharma ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2021 | 279M 25.67M | Sales 2022 | 305M 28.09M | Capitalization | 701M 64.56M |
---|---|---|---|---|---|
Net income 2021 | 24M 2.21M | Net income 2022 | -4M -369K | EV / Sales 2021 | 2.96 x |
Net cash position 2021 | 34.36M 3.17M | Net Debt 2022 | 47.73M 4.4M | EV / Sales 2022 | 2.45 x |
P/E ratio 2021 |
34.6
x | P/E ratio 2022 |
-144
x | Employees | 78 |
Yield 2021 |
3.87% | Yield 2022 |
4.75% | Free-Float | 42.96% |
Latest transcript on Vistin Pharma ASA
1 day | -2.62% | ||
1 week | -2.19% | ||
Current month | -1.76% | ||
1 month | -2.19% | ||
3 months | -3.88% | ||
6 months | -3.88% | ||
Current year | -4.29% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 20-02-29 | |
Director of Finance/CFO | - | 20-03-01 | |
Eivind Egeli
CTO | Chief Tech/Sci/R&D Officer | - | 15-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 76 | 20-05-31 | |
Director/Board Member | 62 | 15-03-05 | |
Director/Board Member | 60 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 22.3 | -2.62% | 8,451 |
24-03-26 | 22.9 | +1.33% | 2,308 |
24-03-25 | 22.6 | +2.26% | 530,520 |
24-03-22 | 22.1 | -1.78% | 1,300 |
24-03-21 | 22.5 | -1.32% | 3,446 |
Real-time Oslo Bors, March 27, 2024 at 09:20 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-4.29% | 91.61M | |
+28.67% | 46.19B | |
+18.57% | 22.88B | |
+20.11% | 14.18B | |
+0.55% | 12.63B | |
+46.16% | 12.07B | |
-1.55% | 7.85B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+7.37% | 5.14B |